Parabilis Medicines
PBLS · NASDAQ
$27.08+$1.73 (+6.82%)TodayMarket closed ·
Prev close $25.35
Key indicators
PBLS profitability and balance sheet ratios
EPS -$0.4247 in Q2 FY26.
| Period | EPS |
|---|---|
| Mar 2025 | -$0.3244 |
| Dec 2025 | -$1.23 |
| Mar 2026 | -$0.3836 |
| Q2 FY26 | -$0.4247 |
Where the money went
Q2 FY26, from revenue to net income
Parabilis Medicines brought in $0.1M of revenue in Q2 FY26. It made a net loss of $67.0M.
- Revenue
- $0.1M
- Costs, expenses and taxes
- $67.1M
- Net income
- −$67.0M
- Net margin
- -45239.9%
Income statement
Revenue and profit by reporting period
| Line item | Q2 FY26 |
|---|---|
| Revenue | $0.1M |
| Gross profit | $0.1M |
| Operating income | −$50.9M |
| Net income | −$67.0M |
| Diluted EPS | -$2.32 |
Balance sheet
What the company owns and owes at period end
Total assets
Total liabilities
| Line item | Mar 2026 | Jun 2026 |
|---|---|---|
| Total assets | $0.0M | $0.0M |
| Total liabilities | $0.0M | $0.0M |
| Shareholder equity | $0.0M | $0.0M |
| Cash and short-term investments | $0.0M | $0.0M |
| Total debt | $0.0M | $0.0M |
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.